Anthem Biosciences, a leading player in the contract research and manufacturing services (CRAMS) space, is set to make its stock market debut on July 21. Ahead of the listing, the grey market premium for the company’s initial public offering has climbed steadily, currently indicating a premium of over 23 percent above the issue price. This strong grey market activity suggests that the IPO could witness a robust listing backed by strong investor interest.
The company’s IPO received a healthy response during the subscription period, with strong participation from institutional investors, high-net-worth individuals, and retail investors. The public issue was oversubscribed multiple times, a clear indication of investor confidence in the company’s growth prospects and sectoral strength.
Anthem Biosciences operates primarily in the biotechnology and pharmaceutical sector, providing research and manufacturing services to global pharma clients. The company has built a solid reputation in the industry for its capabilities in drug discovery, development, and commercial manufacturing. With a client base that includes global pharmaceutical giants, Anthem has positioned itself as a trusted partner for end-to-end drug development services.
Analysts believe that the growing demand for outsourced research and manufacturing in the pharmaceutical sector is likely to benefit companies like Anthem Biosciences in the long run. The company’s strategic expansion plans, strong R and D infrastructure, and operational efficiency have added to the positive outlook.
The IPO proceeds are expected to be used for capacity expansion, working capital needs, and repayment of existing borrowings. According to the company’s prospectus, Anthem Biosciences is also looking to enhance its infrastructure to cater to increasing demand for CRAMS services in regulated and emerging markets.
The strong grey market premium reflects this optimism. Grey market trends, while unofficial, often provide a near-term indicator of how an IPO might perform on listing day. With a premium of over 23 percent being reported, market experts are predicting that Anthem Biosciences is likely to see an enthusiastic debut on the stock exchange.
In addition to its strong financials, Anthem’s listing comes at a time when investor sentiment in the pharma and biotech sectors is improving. After a volatile period, the sector is regaining traction due to increased global healthcare investments and continued innovation in drug development.
Brokerage houses tracking the IPO have issued positive reviews, citing the company’s consistent revenue growth, healthy margins, and future growth potential. Most have advised long-term investors to consider holding the stock beyond listing to benefit from future growth and market expansion.
As the listing date approaches, all eyes will be on how Anthem Biosciences performs on its debut. A successful listing will not only validate market expectations but also reinforce investor interest in quality pharmaceutical and biotech companies entering the stock market.
